Paolo Tarantino, Vivian Saykaly Visiting Professor in Medical Oncology at McGill University Health Centre, Clinical Research Fellow at Dana-Farber Cancer Institute, Research Fellow at Harvard Medical School, shared NEJM’s post on X, adding:
“Truck test.
A particularly neat feature of this trial: it compared an unconjugated topo1 inhibitor (topotecan) vs a conjugated topo1 inhibitor, demonstrating the impact of the ADC delivery system.”
Quoting NEJM’s post:
“Presented at WCLC26:
Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher.”
Title: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
Authors: Yuanyuan Zhao, Hongxu Liu, Xiangjiao Meng, Zhihua Liu, Yan Yu, Yulong Zheng, Longhua Sun, Runxiang Yang, Jian Liu, Yanqiu Zhao, Lin Wu, Lei Yang, Zhiye Zhang, Mingjun Li, Peng Zhang, Yan Zhang, Hua Zhong, Jiuwei Cui, Zhangzhou Huang, Yanwei Yin, Manxiang Li, Fan Tong, Dan Xue, Dongqing Lv, Xufeng Li, Xian Zhang, Steve Chin, Jiaqiang Cai, Tongtong Xue, Yan Huang, Hongyun Zhao, Li Zhang
You can also read:
WCLC 2026 Opens in Seoul: Targeted Therapy Moves Earlier as SCLC Enters a New Therapeutic Era
